CHEK2 and breast carcinoma: Specifically, PVs in PALB2, ATM, CHEK2, RAD51C, and RAD51D are associated with increased lifetime breast cancer risk, ranging from 20% to 58%, depending on the defective gene and identified variant, while influenced by family history [3,4,5,6,7].